Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with lenalidomide with or without dexamethasone in newly diagnosed multiple myeloma
NL-OMON47210Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Celgene Corporation. Started Jan 2017; status: completed.
02
Drugs
durvalumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON47210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47210.